We have examined the chicken TP53 tumor suppressor gene in v-src-transformed chicken tumor cells by reverse transcriptase-polymerase chain reaction and deoxyribonucleic acid (DNA) sequencing. Initially, we have detected frequent deletions of variable length in both DNA-binding and oligomerization domains of the TP53 in late as well as early in vitro passages of the chicken tumor cell line PR9692. This tumor cell line shows an immortal phenotype and acquires a metastatic potential that is unique in our experimental model of v-src-induced tumors in congenic chickens. Deletions in TP53 were also detected in an early passage of parallel in vivo subculture of the original v-src-induced tumor. In this case, tumor cells underwent replicative senescence later in tissue culture. Our results suggest that extensive deletions are efficient mechanisms of TP53 inactivation, occurring as early events during the immortalization of v-src-transformed chicken cells. Tumor cells with altered TP53 might, however, still be susceptible to growth control mechanisms, leading to withdrawal from the mitotic cycle in the early stage of the tumor lifeline.

Institute of Molecular Genetics Academy of Sciences of the Czech Republic Flemingovo nám 2 166 37 Prague Czech Republic

Zobrazit více v PubMed

Cell Death Differ. 2000 Aug;7(8):685-96 PubMed

Genes Chromosomes Cancer. 1992 Jan;4(1):1-15 PubMed

Folia Biol (Praha). 2000;46(6):219-25 PubMed

Nat Genet. 1999 Feb;21(2):187-90 PubMed

Science. 1994 Jul 15;265(5170):346-55 PubMed

Nat Rev Cancer. 2003 Apr;3(4):286-95 PubMed

Biochim Biophys Acta. 2002 Jun 21;1602(2):114-30 PubMed

Nature. 1991 Jun 6;351(6326):453-6 PubMed

Oncogene. 2000 Jun 29;19(28):3164-71 PubMed

Folia Biol (Praha). 2002;48(4):126-38 PubMed

Mol Cell. 1999 Dec;4(6):915-24 PubMed

Exp Cell Res. 2000 Jan 10;254(1):1-13 PubMed

Cell. 2000 Jan 7;100(1):57-70 PubMed

Immunogenetics. 1992;35(5):309-15 PubMed

Oncogene. 2001 Aug 23;20(37):5118-23 PubMed

Adv Cancer Res. 2001;82:55-84 PubMed

Cancer Cell. 2002 Apr;1(3):289-98 PubMed

Folia Biol (Praha). 2000;46(1):17-23 PubMed

Nucleic Acids Res. 1988 Dec 9;16(23):11383 PubMed

Nat Genet. 1992 Apr;1(1):45-9 PubMed

J Lab Clin Med. 1994 Jun;123(6):817-23 PubMed

Nature. 1999 Jul 29;400(6743):464-8 PubMed

EMBO J. 1995 Apr 3;14(7):1372-81 PubMed

Vaccine. 2001 Aug 14;19(31):4526-35 PubMed

Genes Dev. 1999 Oct 15;13(20):2670-7 PubMed

Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16226-31 PubMed

Oncogene. 1999 Dec 13;18(53):7621-36 PubMed

Cancer Cell. 2002 Nov;2(5):401-13 PubMed

Curr Opin Genet Dev. 2003 Feb;13(1):77-83 PubMed

J Exp Med. 1998 Nov 16;188(10 ):1795-802 PubMed

Genes Dev. 1992 May;6(5):876-87 PubMed

Oncogene. 2001 May 10;20(21):2671-82 PubMed

Nature. 1997 Feb 6;385(6616):544-8 PubMed

Science. 1998 Jan 16;279(5349):349-52 PubMed

Immunogenetics. 1994;40(4):257-65 PubMed

Curr Opin Cell Biol. 1998 Apr;10(2):262-7 PubMed

Cancer Res. 1992 Sep 1;52(17):4773-8 PubMed

Int J Cancer. 1993 Apr 1;53(6):983-7 PubMed

Nature. 2001 May 17;411(6835):342-8 PubMed

Biotechniques. 2000 Aug;29(2):234-6 PubMed

Cell Growth Differ. 1995 Oct;6(10):1225-34 PubMed

J Clin Oncol. 2001 Mar 1;19(5):1405-13 PubMed

Exp Cell Res. 2002 Jan 15;272(2):199-208 PubMed

Oncogene. 2000 Nov 20;19(49):5636-42 PubMed